Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2021-03-24 Capital/Financing Update
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details a contract amendment between Daewoong Pharmaceutical and Evolus, Inc., including changes to contract value, duration, and geographic scope. Since this is a specific regulatory disclosure of a material business contract and does not fit into categories like M&A (TAR) or financial reports, it is classified as a general Regulatory Filing (RNS).
2021-03-24 Korean
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Daewoong regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) for the export of Fexuprazan to China. This is a material business event disclosure required by regulatory authorities in Korea. Since it details a specific commercial contract and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2021-03-18 Korean
현금ㆍ현물배당결정(자회사의 주요경영사항)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding a decision on cash dividends ('현금ㆍ현물 배당 결정') by a company. It specifies the dividend amount per share, the total dividend amount, the record date, and the payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2021-03-18 Korean
타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewoong regarding the acquisition of shares in its subsidiary, Daewoong Pharmaceutical. It details the number of shares, acquisition amount, purpose, and board resolution date. This type of disclosure regarding corporate investment and capital structure changes falls under the 'Regulatory Filings' category as it is a specific corporate action announcement that does not fit into more specialized categories like M&A (which usually implies external takeovers) or Share Issue/Capital Change (which usually implies changes to the company's own equity structure).
2021-03-18 Korean
주요사항보고서(자기주식처분결정)(자회사의 주요경영사항)
Transaction in Own Shares Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서' (Major Matters Report) regarding the '자기주식 처분 결정' (Decision to Dispose of Treasury Shares). It details the number of shares to be sold, the price, the purpose (R&D investment), and the counterparty (the parent company). Since the document reports the company's decision to sell its own shares (a share repurchase/disposal event), it falls under the 'Transaction in Own Shares' category.
2021-03-18 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Daewoong Co., Ltd. for the fiscal year 2020. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements. This is a formal audit document, not an annual report (10-K) which would include management discussion and analysis, business overview, and other narrative sections. Therefore, it is classified as an Audit Report. FY 2020
2021-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.